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Sinai, New York, New York, USAIntroduction: Obstetric-related acute kidney injury (AKI) is associated with adverse outcomes for mother
and fetus, particularly in low-income countries. However, laboratory-independent tools to facilitate diag-
nosis are lacking. We assessed the diagnostic performance of a salivary urea nitrogen (SUN) dipstick to
detect obstetric-related acute kidney disease in Malawi.
Methods: Women at high risk for AKI admitted to an obstetric unit in Blantyre, Malawi, were recruited
between 21 September and 11 December 2015. Patients underwent serum creatinine (SCr) testing
alongside measurement of SUN using a dipstick on admission, and every 48 hours thereafter if evidence of
kidney disease was found.
Results: A total of 301 patients were included (mean age 25.9 years, 11% HIV positive). Of the patients, 23
(7.6%) had AKI, stage 1 in 47.8%, most commonly due to preeclampsia/eclampsia. Mean presenting SCr
values were 108.8  21.8 mmol/l (1.23  0.25 mg/dl), 118  34.45 mmol/l (1.33  0.39 mg/dl), and
136.1  30.4 mmol/l (1.54  0.34 mg/dl) in AKI stages 1 to 3 respectively. SUN > 14 mg/dl had a sensitivity of
12.82% and a speciﬁcity of 97.33% to detect acute kidney disease; the area under the receiver operating
characteristic curve was 0.551. In patients with normal SUN on admission, perinatal mortality was 11.8%,
and was 25.0% if SUN was > 14 mg/dl (P ¼ 0.18).
Conclusion: The SUN dipstick was speciﬁc but insensitive when used to diagnose obstetric-related AKI.
Limited biochemical derangement and low salivary urea concentrations due to physiological changes in
pregnancy, as opposed to a technical limitation of the dipstick itself, are the likely reason for the lack of
sensitivity in this study.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A cute kidney injury (AKI) is a global health prob-lem, which currently leads to preventable deaths
in young persons in the poorest parts of the world.1,2
This is particularly the case in sub-Saharan Africa,
where AKI is common and severe, leading to adverse
outcomes in many of those affected.3 In Malawi, a
low-income country in southeast Africa, 21% of
general medical admissions have kidney injury atspondence: Rhys D. R. Evans, UCL Centre for Nephrology,
Free Hospital, Pond Street, London, UK, NW3 2QG.
l: rhysdrevans@gmail.com
ved 17 August 2017; revised 24 September 2017; accepted 2
er 2017; published online 6 October 2017presentation and in-hospital mortality is 44% in those
with AKI, despite free access to tertiary nephrology
services including renal replacement therapy.4
Although detailed data on the epidemiology of AKI
in developing countries including its progression and
subsequent outcomes are lacking, reports suggest that
obstetric-related kidney disease contributes signiﬁ-
cantly to the overall burden of AKI in this part of the
world.5 A lack of consistent antenatal care in
sub-Saharan Africa means that obstetric-related
disease, including AKI, may present late, with poten-
tially disastrous outcomes for both mother and fetus.6–8
Early recognition of AKI is an essential step in
allowing timely treatment in efforts to improve patientKidney International Reports (2018) 3, 178–184
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Diagnosis of AKI is highly dependent on the
measurement of serum creatinine (SCr), which is almost
universally available in high-income countries; how-
ever it is often not available in less privileged health
care settings. In sub-Saharan Africa, obstetric patients
are managed largely in district hospitals and commu-
nity health centers, where SCr tests are unavailable,
creating a signiﬁcant barrier to the management of AKI.
The salivary urea nitrogen (SUN) dipstick is a
noninvasive and simple diagnostic tool that provides
point-of-care estimation of renal function at very low
cost.10,11 It does not require electricity or refrigerated
storage of reagents and therefore may be used in the
remotest parts of the world. We have previously
demonstrated, in both developed and resource-limited
settings, that the SUN dipstick demonstrates good
diagnostic performance to detect kidney injury in adult
medical patients with acute and chronic kidney dis-
ease, albeit with less sensitivity at lower levels of
SUN.10,12–14 In this study, we assessed the performance
of the SUN dipstick to detect obstetric-related AKI in
Malawi.
METHODS
Study Design and Setting
We conducted a prospective observational study at
Queen Elizabeth Central Hospital (QECH) in Blantyre,
Malawi. This hospital acts as a district hospital for
Blantyre and also provides tertiary obstetric and
nephrology care to the southern region of Malawi. The
majority of obstetric admissions are from Blantyre
district, encompassing both urban and rural
populations, and the obstetric unit delivers approxi-
mately 12,000 babies per year. Despite its being ranked
as one of the poorest countries worldwide, health care
in Malawi is government funded and provided to all
free at the point of delivery. At QECH, this includes
access to a high-dependency obstetric unit and hemo-
dialysis for AKI.
Participants
We included women admitted to QECH obstetric
department who were > 20 weeks’ gestation
or < 6 weeks postpartum presenting with conditions
predetermined as being at risk of leading to AKI. These
were admissions with a working diagnosis of the
following: gestational hypertension, preeclampsia,
eclampsia, antepartum hemorrhage, postpartum hem-
orrhage, sepsis, renal failure (diagnosed by admitting
team prior to study recruitment), and heart failure
(Supplementary Table S1).
All participants provided written informed consent.
The University of Malawi, College of MedicineKidney International Reports (2018) 3, 178–184Research Ethics Committee, approved the study (ref.
P.11/14/1660).
Data Collection
Patients were enrolled between 21 September and 11
December 2015. Those fulﬁlling the inclusion criteria
were assessed within 48 hours of admission. Baseline
clinical data were recorded, and screening for kidney
disease (community-acquired) was undertaken with a
SCr alongside simultaneous measurement of SUN using
a dipstick (Integrated Biomedical Technology, Elkhart,
IN).10,12–14 Patients were excluded if they were unable
to undergo concomitant measurement of both SCr and
SUN.
A SCr of > 82mmol/l was considered to be elevated,
predeﬁned as 2 SDs above the mean in the third
trimester of pregnancy.15 Patients with elevated SCr
were managed jointly by the obstetric and nephrology
teams, and the nature (as per deﬁnitions below) and
cause of kidney injury were determined. The women
underwent daily measurement of SCr and urine output,
and further measurement of SUN dipstick and serum
urea at 48 hours. The obstetric team alone managed
patients without raised SCr on admission.
Patients and neonates were followed up until hos-
pital discharge. Maternal and fetal outcomes (gesta-
tional age at delivery, birth weight, ﬁrst Apgar score,16
in-hospital maternal and perinatal mortality) were
recorded in the entire study population.
SUN Measurement
After a period of 15 minutes without eating or drink-
ing, patients provided unstimulated saliva into a plastic
cup, and a 50-ml quantity was used to moisten the test
pad of a colorimetric SUN dipstick. The change in color
of the test pad was assessed at 1 minute and compared
to 6 reference pads corresponding to increasing SUN
concentrations: 5 to 14 mg/dl (pad 1), 15 to 24 mg/dl
(pad 2), 25 to 34 mg/dl (pad 3), 35 to 54 mg/dl (pad 4),
55 to 74 mg/dl (pad 5), and $ 75 mg/dl (pad 6)
(Supplementary Figure S1). During analysis, SUN was
transformed to a continuous variable by converting
the test pad result to the midpoint for each range
(e.g., a SUN result of 514 mg/dl was transformed to
9.5 mg/dl).
Serum Creatinine and Urea Measurement
SCr and urea were measured by the Jaffe and urease
methods, respectively, using either a Flexor Junior
Clinical Chemistry Analyzer (Vital Scientiﬁc, Dieren,
Netherlands) or a Mindray Chemistry Analyzer BS-120
(Shenzen Mindray Bio-Medical Electronics Company,
Shenzen, China) in a local laboratory. Analyzers were
calibrated in accordance with the manufacturer’s
instructions.179
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AKI and CKD were deﬁned and staged by Kidney
Disease Improving Global Outcomes (KDIGO)
criteria.17,18 Patients with elevated SCr (>82 mmol/l) on
admission that did not fulﬁll KDIGO criteria for AKI or
CKD were deﬁned, by our own deﬁnition, as having
acute kidney disease (AKD) without AKI. Any acute
kidney disease encompassed both AKI and AKD
without AKI. Patients with normal SCr on admission
were deemed as having no kidney disease (NKD)
(Supplementary Table S2).
The nephrology study team determined the
primary cause of AKI. Perinatal mortality was deﬁned
as fetal death after 20 weeks’ gestation (stillbirth or
termination of pregnancy) or in-hospital neonatal
death.Outcome Measures
The primary outcome was the diagnostic performance
of the SUN dipstick to detect obstetric-related acute
kidney disease (AKI and AKD without AKI). Secondary
outcomes were comparison of SUN concentrations in
those with and without AKI, and assessment of
maternal and perinatal in-hospital outcomes (gesta-
tional age, birth weight, ﬁrst Apgar score, maternal and
perinatal mortality) according to the presence of AKI
and SUN results.Figure 1. Cohort description. AKD, acute kidney disease; AKI, acute kidn
salivary urea nitrogen.
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Descriptive data are presented as mean  SD and as
median  interquartile range (IQR), depending on the
distribution of data and the standard parametric and
nonparametric tests used. Diagnostic performance of
SUN was determined by sensitivity and speciﬁcity, and
by the area under the receiver operating characteristic
(ROC) curve. The optimal threshold of SUN to diagnose
kidney disease was calculated according to the Youden
Index.
Statistical analysis was performed using Graphpad
Prism version 7 (www.graphpad.com). A P value
of < 0.05 was considered statistically signiﬁcant.RESULTS
Cohort Description
A total of 321 patients at risk for obstetric-related AKI
were admitted, and 301 were enrolled (Figure 1).
The mean age of the entire cohort was 25.9  6.45
years. Of the patients, 33 (11.0%) were HIV positive, 30
of whomwere on antiretroviral therapy. Eleven patients
(3.7%) had known hypertension, but other comorbid-
ities were rare. A total of 106 patients (35.2%) had used a
nephrotoxin prior to admission, including nonsteroidal
anti-inﬂammatory drugs (n ¼ 65) and traditional rem-
edies (n ¼ 11). Presenting conditions leading to risk of
AKI and inclusion in the study are outlined in Table 1.ey injury; CKD, chronic kidney disease; SCr, serum creatinine; SUN,
Kidney International Reports (2018) 3, 178–184
Table 1. Study inclusion diagnoses
Inclusion diagnosis Patients, n (%)
Hypertension in pregnancy 57 (18.9%)
Preeclampsia 80 (26.6%)
Eclampsia 15 (5.0%)
Antepartum hemorrhage 39 (13.0%)
Postpartum hemorrhage 37 (12.3%)
Sepsisa 47 (15.6%)
Renal failure 0 (0.0%)
Cardiac failure 0 (0.0%)
Multiple diagnoses aboveb 26 (8.6%)
aCauses of sepsis: endometritis, n ¼ 14; malaria, n ¼ 11; gastroenteritis, n ¼ 10;
respiratory infection, n ¼ 6; wound infection, n ¼ 4; peritonitis, n ¼ 1; chorioamnionitis,
n ¼ 1; unclear, n ¼ 4.
bPrimary cause for inclusion in those with multiple reasons: hypertension in pregnancy,
n ¼ 4; preeclampsia, n ¼ 9; eclampsia, n ¼ 2; antepartum hemorrhage, n ¼ 5;
postpartum hemorrhage, n ¼ 2; sepsis, n ¼ 4.
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(14.3%) of multiple pregnancies. A total of 75 patients
(24.9%) had a history of previous adverse fetal
outcome (any of previous stillbirth, miscarriage, early
or late neonatal death). The majority of patients
(n ¼ 293; 97.3%) had received some form of antenatal
care, and 6 (3.0%) of the 199 patients who presented
postpartum had delivered at home.
Of the total number of patients enrolled, 23 patients
(7.6%) had AKI (stage 1, n ¼ 11 [47.8%]; stage 2, n ¼ 7
[30.4%]; stage 3, n ¼ 5 [21.8%]. The primary causes of
AKI were preeclampsia/eclampsia (n ¼ 18 [78.3%]),
antepartum hemorrhage (n ¼ 3 [13.1%]), and sepsis
(n ¼ 2 [8.6%]). Mean presenting SCr values were
62.37  23.27 mmol/l (0.71  0.26 mg/dl) in all patients
(Figure 2), and 108.8  21.8 mmol/l (1.23  0.25 mg/dl),
118  34.45 mmol/l (1.33  0.39 mg/dl), and
136.1  30.4 mmol/l (1.54  0.34 mg/dl) in AKI stages 1
to 3 respectively. No patient required renal replace-
ment therapy.
SUN and Urea Measurement
In patients without evidence of kidney disease, SUN on
admission was 5 to 14 mg/dl (testpad 1) in 255 patientsFigure 2. Presenting serum creatinine values in the entire study
population. The blue line at 82 mmol/l represents upper limit of
normal range.
Kidney International Reports (2018) 3, 178–184(97.3%), 15 to 24 mg/dl (testpad 2) in 6 patients (2.3%),
and 25 to 34 mg/dl (testpad 3) in 1 patient (0.4%). In
patients with kidney disease, SUN on admission was 5
to 14 mg/dl (testpad 1) in 34 patients (87.2%), 15 to
24 mg/dl (testpad 2) in 3 patients (7.7%), and 25 to
34 mg/dl (testpad 3) in 2 patients (5.1%). The
mean serum urea was 5.36  3.89 mmol/l (blood urea
nitrogen [BUN] ¼ 15.08  10.92 mg/dl) in patients with
kidney disease who had it measured at 48 hours, and
the mean SUN was 10.93  3.78 mg/dl in these patients
at this time point.Diagnostic Performance of SUN
A SUN result of >14 mg/dl (i.e., greater than testpad 1)
was the optimal threshold to diagnose kidney disease
(Youden Index¼ 0.10); this had a sensitivity of 12.82%
and a speciﬁcity of 97.33% to detect acute kidney
disease (AKI or AKD without AKI). The area under the
ROC curve was 0.551 (Figure 3).Outcome Analyses
Maternal outcomes were determined in 252 patients;
there was 1 maternal death. This was in a patient with
NKD and SUN 15 to 24 mg/dl (testpad 2) on admission
who presented at 24 weeks with eclampsia.
Fetal outcomes were determined in 266 cases. Mean
gestational age at birth was 36.54  3.9 weeks; fetal
weight was 2.7  1.2 kg; and ﬁrst Apgar score was
6.4  2.8. There was no signiﬁcant difference in these
parameters when assessed according to the presence of
AKI or SUN levels.Figure 3. Receiver operating characteristic curve for salivary urea
nitrogen (SUN) > 14 mg/dl (i.e., SUN dipstick greater than testpad 1)
to detect acute kidney disease (acute kidney injury [AKI] and acute
kidney disease without AKI). AUC, area under the curve.
181
CLINICAL RESEARCH RDR Evans et al.: SUN Dipstick to Detect Obstetric-Related Kidney Disease in MalawiPerinatal mortality was 12.2% in NKD and 13.0%
in AKI (P > 0.99). In those mothers with SUN 5 to 14
mg/dl (testpad 1) on admission, perinatal mortality was
11.8%, and in mothers with SUN > 14 mg/dl (greater
than testpad 1) it was 25.0% (P ¼ 0.18).
DISCUSSION
Obstetric-related acute kidney disease is common in
low- and middle-income countries worldwide; howev-
er, simple, inexpensive, laboratory-independent tools
for its diagnosis are currently lacking. In this study, we
tested the performance of a SUN dipstick to detect
obstetric-related acute kidney disease in a low-resource
setting in southern Africa.
Main Findings
We screened 301 patients at high risk for obstetric AKI
with a serum creatinine and SUN dipstick on admission
to a tertiary hospital in Malawi over a 12-week period
in 2015. In a cohort with predominantly mild AKI and
limited biochemical derangement, a SUN result of >14
mg/dl (i.e., greater than testpad 1) had a sensitivity of
12.82% and a speciﬁcity of 97.33% to detect acute
kidney disease (AKI or AKD without AKI). The peri-
natal mortality rate in mothers with an elevated SUN on
admission was 25%.
Interpretation
Urea enters saliva through diffusion transport and,
alongside bicarbonate, is responsible for the buffering
capacity of this ﬂuid. Its presence in saliva was ﬁrst
described in 1841 by Wright, and over the last 30 years
there have been several reports of its correlation with
serum urea and its potential use in the diagnosis of
kidney disease (summarized in Supplementary
Table S3). In studies in which salivary urea was
measured in a laboratory, there has been a consistent
positive correlation between serum and saliva urea, with
correlation coefﬁcients ranging from 0.51 to 0.98.19–25 In
most cases, salivary urea concentrations are less than
serum urea, with salivary urea (variety of cut-off con-
centrations) having a sensitivity of 80% to 100% and a
speciﬁcity of 71% to 100% to detect kidney disease
(using a variety of deﬁnitions, but including patients
with both acute and chronic kidney disease).
In 2007, a dipstick was developed to measure SUN at
the point of care. It has since been demonstrated that
salivary urea measured by this method correlates with
serum urea in controls and patients with acute and
chronic kidney disease (r ¼ 0.630.6910,12) and
performs well in diagnosing kidney disease and
assessing its response to treatment in both developed
and resource-poor settings13,14 (Supplementary
Table S4). Most recently, in a general medical cohort182with predominantly severe AKI in Malawi, we
demonstrated a SUN > 14 mg/dl (testpad > 1) had a
sensitivity of 71% and a speciﬁcity of 87% to detect
acute kidney disease.14 Speciﬁcity increased further if
the dipstick result was combined with patient-reported
oliguria. However, in all studies to date, there has been
a lower accuracy of the SUN dipstick at lower levels of
BUN (< 50 mg/dl), suggesting that the dipstick per-
forms less well in patients with milder AKI and more
limited biochemical derangement.
In the current study, measurement of SUN using the
dipstickwas highly speciﬁc but insensitivewhenused to
diagnose obstetric-related acute kidney disease in a
cohort of patients with relatively modest elevations of
SCr and urea. The overall performance of the dipstick
was poor, with an area under the ROC curve of 0.551 for a
SUN > 14 mg/dl to detect kidney disease. Two possi-
bilities could account for this: ﬁrst, the dipstick may not
have accurately measured salivary urea (i.e., a technical
problem with the dipstick itself); and second, the
dipstick may have accurately measured salivary urea,
but salivary urea levels may not have been signiﬁcantly
raised in this obstetric cohort with acute kidney disease.
We believe that the latter hypothesis is more
likely. Although we did not measure salivary urea by
laboratory methods alongside the dipstick, we know
that the dipstick has been tested against known urea
concentrations in aqueous solution and, moreover,
that it has demonstrated good correlation with serum
urea and reasonable sensitivity to diagnose kidney
disease in other cohorts in which it has been trialed.
A key difference in this study compared to previous
work was the obstetric nature of the cohort. The
physiological changes during pregnancy mean that
obstetric patients represent a unique environment,
with signiﬁcant increases in glomerular ﬁltration rate
and circulating volume, resulting in reductions in both
serum urea and SCr throughout pregnancy.15,26 This
results in difﬁculties in recognizing renal impairment,
even when using laboratory-measured SCr and serum
urea.26 Changes in salivary urea are not well charac-
terized in pregnant women, but it would be reasonable
to assume that reductions in serum urea are reﬂected
by reductions in salivary urea concentration. The
relatively mild nature of kidney disease, alongside the
low-protein diet and muscle mass in young women in
Malawi more generally, may have also contributed to
low salivary urea concentrations in this obstetric
cohort. Of note, mean BUN was 15.08 mg/dl when
measured at 48 hours postadmission in a small number
of patients with kidney disease; due to logistic and
ﬁnancial restrictions, we did not measure BUN on
admission. Moreover, we know from previous work
that SUN tends to underestimate BUN.Kidney International Reports (2018) 3, 178–184
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hormonal or biochemical changes in the composition of
saliva in pregnancy may have affected the test, in
particular pH. The test depends on urease within the
test pad, which catalyses the conversion of urea to
ammonia and hydroxyl ions, with subsequent detec-
tion of the resulting change in pH. Changes in salivary
pH in pregnancy may affect this process,27 including in
relation to alterations of oral bacterial ﬂora,28,29 albeit
with the strip having a control pad for any gross ab-
normality in salivary pH at baseline.
Despite the diagnostic performance being worse
than we had anticipated, the SUN dipstick did suggest
in this study, as it has done in previous studies, that it
may provide prognostic information. In general medi-
cal patients in Malawi, elevated SUN on admission was
an independent predictor of in-hospital mortality.14 In
this cohort, perinatal mortality was 25% in patients
with elevated SUN (> 14 mg/dl) on admission,
compared to 11.8% in patients with normal SUN (514
mg/dl), although, given the limited numbers of patients
with elevated SUN in the cohort as a whole, ﬁrm
conclusions are difﬁcult to make.
Study Strengths and Limitations
To the best of our knowledge, this is the ﬁrst study to
assess the performance of a point-of-care, laboratory-
independent tool to diagnose obstetric-related kidney
disease in a resource-limited setting. It was undertaken
prospectively in a large cohort of patients at risk for
kidney disease, with outcome data in the majority.
Through the inclusion of a novel cohort, it comple-
ments other studies investigating the use of the SUN
dipstick across different settings in sub-Sahara Africa,
and conﬁrms the high speciﬁcity of the test.
Obstetric patients provide a unique challenge in
diagnosing AKI. Few women had documented baseline
SCr, and a lack of a “normal” glomerular ﬁltration rate in
pregnancy meant that imputed baselines assuming
normal renal function were unable to be used like they
can in the nonpregnant population. We were unable to
determine those women with underlying CKD.
Furthermore, local practical challenges such as a lack of
urine measuring jugs, lack of catheter bags, and rela-
tively low literacy rates meant that accurate estimation
of urine output was difﬁcult. Some cases of kidney dis-
ease may have been missed; AKI may have been mis-
classiﬁed as AKD; and severity may have been
underestimated. We detected kidney disease that was
present on admission, but the development of AKI in
hospital was not assessed. This study also occurred
outside of malaria season, anecdotally the most common
cause of obstetric AKI requiring renal replacement
therapy in our experience. Although it would have beenKidney International Reports (2018) 3, 178–184possible, we did not use the SUN dipstick in patients
with signiﬁcantly reduced consciousness in this study,
and hence we may have missed the most severe AKI.
Although we undertook this study in a truly
resource-poor setting, its generalizability to the rest of
Malawi and Africa need to be interpreted with caution.
Malawi is unique within the region for providing
health care free at the point of delivery, including, as
was the case in this study, tertiary obstetric and
nephrology care. Severity of AKI and outcomes may be
worse in more rural settings within Malawi that lack
this level of care, and in neighboring countries where
ﬁnancial restrictions may limit access to care. We are
currently investigating the use of the dipstick in
district and community settings in Malawi. We did not
measure serum urea at recruitment or salivary urea by
laboratory methods alongside the dipstick, and we aim
to do this in upcoming studies.
In conclusion, in this study, measuring SUN using a
dipstick was speciﬁc but insensitive when used to di-
agnose obstetric-related acute kidney disease in
Malawi. Low salivary urea concentrations in this
cohort, in combination with the reduced accuracy of
the dipstick at lower levels of BUN, are the likely main
drivers for the lack of sensitivity seen in the study. The
development of laboratory-independent diagnostic
tools remains essential in the management of kidney
disease across sub-Saharan Africa and other resource-
poor settings worldwide. A modiﬁed SUN dipstick
with increased sensitivity at the lower ranges of SUN is
currently under development, with plans to test this in
both pregnant and nonpregnant patients with kidney
disease.DISCLOSURE
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SUPPLEMENTARY MATERIAL
Figure S1. Reference pads (16) of the salivary urea
nitrogen (SUN) dipstick, with increasing green color
corresponding to increased urea nitrogen range. The
change in color of the test pad is compared to these
reference pads.
Table S1. Study inclusion criteria and deﬁnitions.
Table S2. Deﬁnitions of kidney disease.
Table S3. Selected studies of laboratory-measured salivary
urea, its correlation with serum urea, and its performance
in the diagnosis of kidney disease.183
CLINICAL RESEARCH RDR Evans et al.: SUN Dipstick to Detect Obstetric-Related Kidney Disease in MalawiTable S4. Studies of dipstick-measured salivary urea, its
correlation with serum urea, and its performance in the
diagnosis of kidney disease.
Supplementary material is linked to the online version of
the paper at www.kireports.org.REFERENCES
1. Mehta RL, Cerdá J, Burdmann EA, et al. International Society
of Nephrology’s 0by25 initiative for acute kidney injury (zero
preventable deaths by 2025): a human rights case for
nephrology. Lancet. 2015;385:2616–2643.
2. Mehta RL, Burdmann EA, Cerdá J, et al. Recognition and
management of acute kidney injury in the International So-
ciety of Nephrology 0by25 Global Snapshot: a multinational
cross-sectional study. Lancet. 2016;387:2017–2025.
3. OlowuWA, Niang A, Osafo C, et al. Outcomes of acute kidney
injury in children and adults in sub-Saharan Africa: a sys-
tematic review. Lancet Glob Health. 2016;4:e242–e250.
4. Evans RDR, Hemmilä U, Craik A, et al. Incidence, aetiology
and outcome of community-acquired acute kidney injury in
medical admissions in Malawi. BMC Nephrol. 2017;18:21.
5. Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an
increasing global concern. Lancet. 2013;382:170–179.
6. Randeree IG, Czarnocki A, Moodley J, et al. Acute renal failure
in pregnancy in South Africa. Ren Fail. 1995;17:147–153.
7. Drakeley AJ, Le Roux PA, Anthony J, et al. Acute renal failure
complicating severe preeclampsia requiring admission to an
obstetric intensive care unit. Am J Obstet Gynecol. 2002;186:
253–256.
8. Kaze FF, Njukeng FA, Kengne A-P, et al. Post-partum trend in
blood pressure levels, renal function and proteinuria in
women with severe preeclampsia and eclampsia in sub-
Saharan Africa: a 6-months cohort study. BMC Pregnancy
Childbirth. 2014;14:134.
9. Cerdá J, Mohan S, Garcia-Garcia G, et al. Acute kidney injury
recognition in low- and middle-income countries. Kidney Int
Rep. 2017;2:530–543.
10. Calice-Silva V, Vieira MA, Raimann JG, et al. Saliva urea ni-
trogen dipstick—a novel bedside diagnostic tool for acute
kidney injury. Clin Nephrol. 2014;82:358–366.
11. Raimann JG, Riella MC, Levin NW. International Society of
Nephrology’s 0by25 initiative (zero preventable deaths from
acute kidney injury by 2025): focus on diagnosis of acute
kidney injury in low-income countries. Clin Kidney J. https://
doi.org/10.1093/ckj/sfw134.
12. Raimann JG, Kirisits W, Gebetsroither E, et al. Saliva urea
dipstick test: application in chronic kidney disease. Clin
Nephrol. 2011;76:23–28.
13. Raimann JG, Calice-Silva V, Thijssen S, et al. Saliva urea ni-
trogen continuously reﬂects blood urea nitrogen after acute
kidney injury diagnosis and management: longitudinal
observational data from a collaborative, international, pro-
spective, multicenter study. Blood Purif. 2016;42:64–72.18414. Evans R, Calice-Silva V, Raimann JG, et al. Diagnostic per-
formance of a saliva urea nitrogen dipstick to detect kidney
disease in Malawi. Kidney Int Rep. 2017;2:219–227.
15. Williams D, Davison J. Chronic kidney disease in pregnancy.
BMJ. 2008;336:211–215.
16. ACOG. The Apgar score. Available at: https://www.acog.org/
Resources-And-Publications/Committee-Opinions/Committee-
on-Obstetric-Practice/The-Apgar-Score. Accessed 6July 6,
2017.
17. KDIGO. Acute kidney injury (AKI). Available at: http://kdigo.
org/guidelines/acute-kidney-injury/. Accessed August 17,
2017.
18. KDIGO. CKD evaluation and management. Available at:
http://kdigo.org/guidelines/ckd-evaluation-and-management/.
Accessed June 17, 2017.
19. Yajamanam N, Vinapamula KS, Sivakumar V, et al. Utility of
saliva as a sample to assess renal function and estimated
glomerular ﬁltration rate. Saudi J. Kidney Dis Transplant.
2016;27:312–319.
20. Pandya D, Nagrajappa AK, Ravi KS. Assessment and corre-
lation of urea and creatinine levels in saliva and serum of
patients with chronic kidney disease, diabetes and hyper-
tension—a research study. J Clin Diagn Res. 2016;10:
ZC58–ZC62.
21. Lasisi TJ, Raji YR, Salako BL. Salivary creatinine and urea
analysis in patients with chronic kidney disease: a case con-
trol study. BMC Nephrol. 2016;17:10.
22. Seethalakshmi C, Koteeswaran D, Chiranjeevi V. Correla-
tion of serum and salivary biochemical parameters in end
stage renal disease patients undergoing hemodialysis in
pre and post-dialysis state. J Clin Diagn Res. 2014;8:
CC12–CC14.
23. Zúñiga ME, Estremadoyro LO, León CP, et al. Validation of the
salivary urea test as a method to diagnose chronic kidney
disease. J Nephrol. 2012;25:431–436.
24. Cardoso EML, Arregger AL, Tumilasci OR, et al. Assessment
of salivary urea as a less invasive alternative to serum
determinations. Scand J Clin Lab Invest. 2009;69:330–334.
25. Sein KT, Arumainayagam G. Correlation between serum urea
and salivary urea. Clin Chem. 1987;33:2303–2304.
26. Acharya A, Santos J, Linde B, et al. Acute kidney injury in
pregnancy—current status. Adv Chron Kidney Dis. 2013;20:
215–222.
27. Rockenbach MI, Marinho SA, Veeck EB, et al. Salivary ﬂow
rate, pH, and concentrations of calcium, phosphate, and sIgA
in Brazilian pregnant and non-pregnant women. Head Face
Med. 2006;2:44.
28. Basavaraju A, Durga SV, Vanitha B. Variations in the oral
anaerobic microbial ﬂora in relation to pregnancy. J Clin
Diagn Res. 2012;6:1489–1491.
29. Liu YL, Nascimento M, Burne RA. Progress toward under-
standing the contribution of alkali generation in dental
bioﬁlms to inhibition of dental caries. Int J Oral Sci. 2012;4:
135–140.Kidney International Reports (2018) 3, 178–184
